Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerating Subretinal Fluid in Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy Treated Using Aflibercept

NCT05662943 is registered in ClinicalTrials.gov with Kim's Eye Hospital as lead sponsor.

NCT NCT05662943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05662943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerating Subretinal Fluid in Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy Treated Using Aflibercept
Lead sponsor
Kim's Eye Hospital
Phase
Observational
Overall status
Completed
Start date
December 5, 2022
Completion date
November 30, 2023
Enrollment
135 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, choroidal neovascularization, polypoidal choroidal vasculopathy